A Phase II Study of Adjuvant Chemotherapy of Tegafur-Uracil for Patients with Breast Cancer with HER2-negative Pathologic Residual Invasive Disease After Neoadjuvant Chemotherapy

There is no consensus on the need for adjuvant chemotherapy for patients with pathological residual invasive breast cancer (non-pCR) after neoadjuvant chemotherapy (NAC). We evaluated the tolerability and safety of tegafur-uracil (UFT) as adjuvant chemotherapy for patients with human epidermal growt...

Full description

Saved in:
Bibliographic Details
Published inAnticancer research Vol. 36; no. 12; pp. 6505 - 6509
Main Authors Tanaka, Satoru, Iwamoto, Mitsuhiko, Kimura, Kosei, Takahashi, Yuko, Fujioka, Hiyoya, Sato, Nayuko, Terasawa, Risa, Kawaguchi, Kanako, Ikari, Ayana, Tominaga, Tomo, Maezawa, Saki, Umezaki, Nodoka, Matsuda, Junna, Uchiyama, Kazuhisa
Format Journal Article
LanguageEnglish
Published Greece 01.12.2016
Subjects
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Breast Neoplasms - drug therapy
Breast Neoplasms - pathology
Chemotherapy, Adjuvant
Female
Humans
Middle Aged
Neoplasm Invasiveness
Prospective Studies
Tegafur - administration & dosage
Uracil - administration & dosage
neoadjuvant chemotherapy
breast cancer
pathologic complete response
Tegafur-uracil
Online AccessGet full text

Cover

More Information
Summary:There is no consensus on the need for adjuvant chemotherapy for patients with pathological residual invasive breast cancer (non-pCR) after neoadjuvant chemotherapy (NAC). We evaluated the tolerability and safety of tegafur-uracil (UFT) as adjuvant chemotherapy for patients with human epidermal growth factor receptor 2-negative breast cancer that resulted in non-pCR after NAC. We treated patients with 270 mg/m UFT per day for 2 years after definitive surgery and radiotherapy, if necessary. In cases with hormone-sensitive cancer, patients received concurrent endocrine therapy. The primary end-point was the rate of completion of scheduled UFT therapy. Secondary end-points included safety and disease-free survival. Twenty-one out of 29 patients (72%) completed the scheduled therapy. Eight patients discontinued the study treatment because of disease recurrence, toxicities, and patients' wish. Excluding liver dysfunction, adverse events were quite mild. Adjuvant UFT therapy after NAC was feasible and safe.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
ISSN:0250-7005
1791-7530
DOI:10.21873/anticanres.11250